4.6 Article

Effect of in vivo loss of GDF-15 on hepatocellular carcinogenesis

Journal

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Volume 134, Issue 7, Pages 753-759

Publisher

SPRINGER
DOI: 10.1007/s00432-007-0336-4

Keywords

hepatocellular carcinoma; growth/differentiation factor-15; transforming growth factor-beta; transgenic/knockout; hPDF; hPLAB; hPTGF-ssPL; hNAG-1

Categories

Funding

  1. PHS HHS [63603] Funding Source: Medline

Ask authors/readers for more resources

Background Growth/differentiation factor-15(GDF-15) is a divergent TGF-beta family member that is expressed following liver injury and carcinogen exposure. GDF-15 expression is highly associated with gastrointestinal cancer stage, size, and metastasis and has been implicated in inhibition of tumor growth and increased tumor invasiveness. The current study sought to determine the effect of GDF-15 ablation on the development of hepatocellular carcinoma (HCC) in vivo. Materials and methods Male mice genetically deleted for the gene encoding GDF-15 (Gdf15(-/-) mice) and wild-type controls were exposed to the hepatocarcinogen diethylnitrosamine (DEN). Mice were killed at 6 months of age and their livers dissected and processed for histology. Tumor number and size relative to total liver area examined were determined. Results At 6 months of age, tumors were identified in 16 of 20 (80%) Gdf15(-/-) mice and 16 of 19 wild-type mice (84%). No significant difference in tumor-occupied area was observed in Gdf15(-/-) mice versus wild-type mice. In addition, no difference in invasiveness was observed in HCC arising in Gdf15(-/-) as compared to wild-type mice. In wild type mice strong immunohistochemical staining for GDF-15 was noted on small HCC foci, whereas a loss of GDF-15 expression was found in a number of advanced HCC tumors. Conclusions Although highly expressed in association with multiple gastrointestinal cancers, and lost in some advanced HCC, genetic ablation of GDF-15 has no apparent effect on HCC tumor formation rate, growth rate or invasiveness in diethylnitrosamine-induced HCC in vivo.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Review Oncology

The Liver-Immunity Nexus and Cancer Immunotherapy

James C. Lee, Michael D. Green, Laura A. Huppert, Christine Chow, Robert H. Pierce, Adil Daud

Summary: Liver metastases have a significant impact on the effectiveness of immune checkpoint inhibitors in patients with solid-tumor malignancies. Multiple clinical and translational studies have shown that liver metastasis leads to systemic immune suppression through the generation of suppressive macrophages and activation of regulatory T-cells. Various interventions, such as radiation therapy and combination checkpoint blockade, have been reported to address liver immune suppression.

CLINICAL CANCER RESEARCH (2022)

Article Oncology

Neoadjuvant Therapy Induces a Potent Immune Response to Sarcoma, Dominated by Myeloid and B Cells

Peter H. Goff, Laura Riolobos, Bonnie J. LaFleur, Matthew B. Spraker, Y. David Seo, Kimberly S. Smythe, Jean S. Campbell, Robert H. Pierce, Yuzheng Zhang, Qianchuan He, Edward Y. Kim, Stephanie K. Schaub, Gabrielle M. Kane, Jose G. Mantilla, Eleanor Y. Chen, Robert Ricciotti, Matthew J. Thompson, Lee D. Cranmer, Michael J. Wagner, Elizabeth T. Loggers, Robin L. Jones, Erin Murphy, Wendy M. Blumenschein, Terrill K. McClanahan, Jon Earls, Kevin C. Flanagan, Natalie A. LaFranzo, Teresa S. Kim, Seth M. Pollack

Summary: This study aims to characterize the changes in the soft-tissue sarcoma (STS) tumor immune microenvironment induced by standard neoadjuvant therapy and provides insights for neoadjuvant immunotherapy trial design. The results show that neoadjuvant therapy significantly increases immune cell infiltration in the tumor and affects the expression of immune-related genes and cytokines. These findings inform the incorporation of immune checkpoint inhibitors and novel immunotherapies into the neoadjuvant setting for STSs.

CLINICAL CANCER RESEARCH (2022)

Article Endocrinology & Metabolism

RANKL Blockade Reduces Cachexia and Bone Loss Induced by Non-Metastatic Ovarian Cancer in Mice

Fabrizio Pin, Alexander J. Jones, Joshua R. Huot, Ashok Narasimhan, Teresa A. Zimmers, Lynda F. Bonewald, Andrea Bonetto

Summary: This study demonstrates that patients with ovarian cancer exhibit evidence of cachexia and increased bone turnover, with high levels of RANKL potentially causing skeletal muscle atrophy and bone resorption. Treatment with antiresorptive and anti-RANKL therapies benefits muscle mass and function in cancer cachexia.

JOURNAL OF BONE AND MINERAL RESEARCH (2022)

Article Geriatrics & Gerontology

Addressing unmet needs for people with cancer cachexia: recommendations from a multistakeholder workshop

Jose M. Garcia, Richard F. Dunne, Kristen Santiago, Lisa Martin, Morris J. Birnbaum, Jeffrey Crawford, Andrew E. Hendifar, Martin Kochanczyk, Cassadie Moravek, Doris Piccinin, Vincent Picozzi, Eric J. Roeland, Wendy K. D. Selig, Teresa A. Zimmers

JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE (2022)

Article Cell Biology

Activin A Causes Muscle Atrophy through MEF2C-Dependent Impaired Myogenesis

Audrey Loumaye, Pascale Lause, Xiaoling Zhong, Teresa A. Zimmers, Laure B. Bindels, Jean-Paul Thissen

Summary: This study investigated the effects of Activin A (ActA) on human skeletal muscle (SM) and in mouse models of cancer-induced cachexia (CC). The results showed that ActA induces myotube atrophy and inhibits the expression and activity of MEF2C, leading to the decrease in MyHC-beta/slow, the main myosin isoform in human muscle cells. Animal models of CC exhibited a decline in MEF2C expression and SM mass, which were both attenuated by ActA inhibition. This study reveals a novel interaction between ActA signaling and MEF2C transcriptional activity in SM atrophy in CC models.

CELLS (2022)

Editorial Material Cell Biology

Editorial: Metabolic Adaptation of Muscle Tissue in Diseases Associated With Cachexia

Federica Cirillo, Teresa A. Zimmers, Laura Mangiavini

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2022)

Article Biology

STAT3 in tumor fibroblasts promotes an immunosuppressive microenvironment in pancreatic cancer

Julia E. Lefler, Catherine B. MarElia-Bennett, Katie A. Thies, Blake E. Hildreth, Sudarshana M. Sharma, Jason R. Pitarresi, Lu Han, Caroline Everett, Christopher Koivisto, Maria C. Cuitino, Cynthia Timmers, Elizabeth O'Quinn, Melodie Parrish, Martin J. Romeo, Amanda J. Linke, G. Aaron Hobbs, Gustavo Leone, Denis C. Guttridge, Teresa A. Zimmers, Gregory B. Lesinski, Michael C. Ostrowski

Summary: Disruption of the STAT3 signaling axis in stromal fibroblasts through genetic ablation of Stat3 slows tumor progression, increases survival, and reshapes the immune-suppressive tumor micro-environment in a PDAC mouse model. Loss of the tumor suppressor PTEN in pancreatic CAFs leads to increased STAT3 phosphorylation and promotes secretion of CXCL1.

LIFE SCIENCE ALLIANCE (2022)

Article Biochemistry & Molecular Biology

Exogenous Oncostatin M induces Cardiac Dysfunction, Musculoskeletal Atrophy, and Fibrosis

Daenique H. A. Jengelley, Meijing Wang, Ashok Narasimhan, Joseph E. Rupert, Andrew R. Young, Xiaoling Zhong, Daniel J. Horan, Alexander G. Robling, Leonidas G. Koniaris, Teresa A. Zimmers

Summary: Musculoskeletal diseases can harm overall health and survival, with the Interleukin-6 family of cytokines, particularly IL-6, playing a role. Oncostatin M (OSM) has negative effects on muscle, bone, and the heart, causing muscle atrophy, bone loss, and cardiac dysfunction.

CYTOKINE (2022)

Review Immunology

Role of CD14 in human disease

Daniel Sharygin, Leonidas G. Koniaris, Clark Wells, Teresa A. Zimmers, Tewfik Hamidi

Summary: The cell surface antigen CD14 acts as a co-receptor for toll-like receptors (TLRs) in macrophages and monocytes, but also has roles in disease responses in epithelial and endothelial cells. CD14 expression is altered in various non-immune cell types in response to disease states, and soluble CD14 can initiate signaling in these cells. This review examines CD14's role in innate immunity and its potential functions in non-immune cells and associated human diseases.

IMMUNOLOGY (2023)

Article Biochemistry & Molecular Biology

Dynamic Alterations to Hepatic MicroRNA-29a in Response to Long-Term High-Fat Diet and EtOH Feeding

Tiebing Liang, Janaiah Kota, Kent E. Williams, Romil Saxena, Samer Gawrieh, Xiaoling Zhong, Teresa A. Zimmers, Naga Chalasani

Summary: MicroRNA-29a (miR-29a) is a fibro-inflammatory molecule that is associated with liver pathological conditions. The effects of a high-fat diet (HFD) combined with different levels of ethanol (EtOH) consumption on miR-29a expression and liver pathobiology were investigated. The study found that miR-29a was up-regulated with increasing levels of EtOH consumption and was associated with less severe liver injury. A high-fat diet and increasing concentrations of EtOH had progressive adverse effects on the liver, without any beneficial effects of low-dose EtOH consumption.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Meeting Abstract Oncology

Oncostatin M modulates tumor-fibroblast crosstalk in pancreatic cancer without protecting against cachexia.

Daenique H. Jengelley, Ashok Narasimhan, Joseph E. Rupert, Xiaoling Zhong, Andrew R. Young, Leonidas G. Koniaris, Teresa A. Zimmers

CANCER RESEARCH (2022)

Meeting Abstract Oncology

Skeletal Muscle Selective Autophagy Receptors are induced PDAC Cachexia

Brittany R. Counts, Ashok Narasimhan, Tara S. Umberger, Emma H. Doud, Amber L. Mosley, Teresa A. Zimmers

CANCER RESEARCH (2022)

Meeting Abstract Oncology

A PILOT INVESTIGATION OF GDF15 IN CHILDREN WITH CANCER

Daniel Runco, Linda Dimeglio, Charles Vanderpool, Danielle Halsey, Teresa Zimmers

PEDIATRIC BLOOD & CANCER (2022)

Article Oncology

Mavorixafor, an Orally Bioavailable CXCR4 Antagonist, Increases Immune Cell Infiltration and Inflammatory Status of Tumor Microenvironment in Patients with Melanoma

Robert H. I. Andtbacka, Yan Wang, Robert H. Pierce, Jean S. Campbell, Melinda Yushak, Mohammed Milhem, Merrick Ross, Katie Niland, Robert D. Arbeit, Sudha Parasuraman, Kris Bickley, Cecilia C. S. Yeung, Lauri D. Aicher, Kimberly S. Smythe, Lu Gan

Summary: The study found that treatment with single-agent mavorixafor can increase CD8+ T-cell infiltration, granzyme B signal, antigen presentation machinery, and both tumor inflammatory signature (TIS) and IFNγ gene expression signature scores. When mavorixafor was combined with pembrolizumab, the increases in the key serum cytokines CXCL9 and CXCL10 were further enhanced. Reported adverse events included diarrhea, fatigue, maculopapular rash, and dry eye, all of which were ≤ grade 3.

CANCER RESEARCH COMMUNICATIONS (2022)

Meeting Abstract Endocrinology & Metabolism

RANKL blockade reduces cachexia and bone loss induced by non-metastatic cancer

Fabrizio Pin, Alexander J. Jones, Joshua R. Huot, Narasimhan Ashok, Teresa A. Zimmers, Lynda F. Bonewald, Andrea Bonetto

JOURNAL OF BONE AND MINERAL RESEARCH (2022)

No Data Available